Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6224604,t1/2,Discontinuation of the treatment produces a fast decay (t1/2 = 62.4 h) of the drug levels.,Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6224604/),h,62.4,4354,DB00603,Medroxyprogesterone Acetate
<,24582292,Cmax,Cmax <2.88 ng/mL and elimination rate constant <0.021 ng/mL/day were associated (p<.05) with BMI increase ≥10%.,A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24582292/),[ng] / [ml],2.88,9990,DB00603,Medroxyprogesterone Acetate
<,24582292,elimination rate constant,Cmax <2.88 ng/mL and elimination rate constant <0.021 ng/mL/day were associated (p<.05) with BMI increase ≥10%.,A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24582292/),[ng] / [d·ml],0.021,9991,DB00603,Medroxyprogesterone Acetate
,19481986,extraction recovery,The lower limit of quantification was 1 ng/mL and extraction recovery was 88.3% on average.,Determination of Tenacissoside A in rat plasma by liquid chromatography-tandem mass spectrometry method and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481986/),%,88.3,12933,DB00603,Medroxyprogesterone Acetate
,1388093,AUC0-144,"Based on the results of RIA analysis, Farlutal tablets produced significantly lower serum MPA concentrations compared with Provera tablets at most sampling times, resulting in statistically lower AUC0-144 for the Farlutal tablet (544 vs 768 ng.hr/ml; -29.2%).",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[h·ng] / [ml],544,16677,DB00603,Medroxyprogesterone Acetate
,1388093,AUC0-144,"Based on the results of RIA analysis, Farlutal tablets produced significantly lower serum MPA concentrations compared with Provera tablets at most sampling times, resulting in statistically lower AUC0-144 for the Farlutal tablet (544 vs 768 ng.hr/ml; -29.2%).",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[h·ng] / [ml],768,16678,DB00603,Medroxyprogesterone Acetate
,1388093,maximum concentration,The Farlutal tablet also had a significantly lower maximum concentration than the Provera tablet (27.8 vs 47.4 ng/ml; -41.4%).,Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[ng] / [ml],27.8,16679,DB00603,Medroxyprogesterone Acetate
,1388093,maximum concentration,The Farlutal tablet also had a significantly lower maximum concentration than the Provera tablet (27.8 vs 47.4 ng/ml; -41.4%).,Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[ng] / [ml],47.4,16680,DB00603,Medroxyprogesterone Acetate
,1388093,time of maximum concentration,"However, there was no significant difference in time of maximum concentration between the tablet formulations (3.71 vs 3.41 hr), indicating that the rates of absorption of the two tablet formulations were comparable.",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),h,3.71,16681,DB00603,Medroxyprogesterone Acetate
,1388093,time of maximum concentration,"However, there was no significant difference in time of maximum concentration between the tablet formulations (3.71 vs 3.41 hr), indicating that the rates of absorption of the two tablet formulations were comparable.",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),h,3.41,16682,DB00603,Medroxyprogesterone Acetate
,1388093,AUC0-144,"Provera granules provided significantly higher serum MPA levels than Provera tablets at 0.5, 1, 1.5, 2, and 6 hours, and the AUC0-144 for Provera granules was higher by 5.47% (810 vs 768 ng.hr/ml).",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[h·ng] / [ml],810,16683,DB00603,Medroxyprogesterone Acetate
,1388093,AUC0-144,"Provera granules provided significantly higher serum MPA levels than Provera tablets at 0.5, 1, 1.5, 2, and 6 hours, and the AUC0-144 for Provera granules was higher by 5.47% (810 vs 768 ng.hr/ml).",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),[h·ng] / [ml],768,16684,DB00603,Medroxyprogesterone Acetate
,1388093,relative bioavailabilities,"The relative bioavailabilities of Provera granules and Farlutal tablets were 105% and 71.2%, respectively, compared with Provera tablets.",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),%,105,16685,DB00603,Medroxyprogesterone Acetate
,1388093,relative bioavailabilities,"The relative bioavailabilities of Provera granules and Farlutal tablets were 105% and 71.2%, respectively, compared with Provera tablets.",Bioavailability of medroxyprogesterone acetate from three oral dosage formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1388093/),%,71.2,16686,DB00603,Medroxyprogesterone Acetate
,30947128,run time,The run time was 6 min and the calibration curve was linear over the range of 0.005-0.15 ng/mL.,Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),min,6,62065,DB00603,Medroxyprogesterone Acetate
,30947128,maximum plasma concentration (Cmax),The estradiol cypionate maximum plasma concentration (Cmax) was 0.14 ± 0.08 ng/mL reached at 16.83 ± 21.07 h and the area under the plasma concentration versus time curve (AUC0-last) was 14.07 ± 6.32 ng.h/mL.,Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),[ng] / [ml],0.14,62066,DB00603,Medroxyprogesterone Acetate
,30947128,area under the plasma concentration versus time curve (AUC0-last),The estradiol cypionate maximum plasma concentration (Cmax) was 0.14 ± 0.08 ng/mL reached at 16.83 ± 21.07 h and the area under the plasma concentration versus time curve (AUC0-last) was 14.07 ± 6.32 ng.h/mL.,Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),[h·ng] / [ml],14.07,62067,DB00603,Medroxyprogesterone Acetate
,30947128,Elimination half-life (t½),"Elimination half-life (t½), apparent volume of distribution (Vd/F), apparent clearance (CL/F) and mean residence time (MRT) were 89.65 ± 76.04 h, 28038 ± 9636 L, 49.02 ± 10.62 L/h and 576.05 ± 238.32 h, respectively, showing that the estradiol cypionate release from the administration site was prolonged and there was no drug accumulation.",Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),h,89.65,62068,DB00603,Medroxyprogesterone Acetate
,30947128,apparent volume of distribution (Vd/F),"Elimination half-life (t½), apparent volume of distribution (Vd/F), apparent clearance (CL/F) and mean residence time (MRT) were 89.65 ± 76.04 h, 28038 ± 9636 L, 49.02 ± 10.62 L/h and 576.05 ± 238.32 h, respectively, showing that the estradiol cypionate release from the administration site was prolonged and there was no drug accumulation.",Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),l,28038,62069,DB00603,Medroxyprogesterone Acetate
,30947128,apparent clearance (CL/F),"Elimination half-life (t½), apparent volume of distribution (Vd/F), apparent clearance (CL/F) and mean residence time (MRT) were 89.65 ± 76.04 h, 28038 ± 9636 L, 49.02 ± 10.62 L/h and 576.05 ± 238.32 h, respectively, showing that the estradiol cypionate release from the administration site was prolonged and there was no drug accumulation.",Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),l,28038,62070,DB00603,Medroxyprogesterone Acetate
,30947128,mean residence time (MRT),"Elimination half-life (t½), apparent volume of distribution (Vd/F), apparent clearance (CL/F) and mean residence time (MRT) were 89.65 ± 76.04 h, 28038 ± 9636 L, 49.02 ± 10.62 L/h and 576.05 ± 238.32 h, respectively, showing that the estradiol cypionate release from the administration site was prolonged and there was no drug accumulation.",Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947128/),h,576.05,62071,DB00603,Medroxyprogesterone Acetate
,10701698,Partition coefficients (log P),"Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),,3.1,75822,DB00603,Medroxyprogesterone Acetate
,10701698,Partition coefficients (log P),"Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),,3.8,75823,DB00603,Medroxyprogesterone Acetate
,10701698,solubilities,"Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),[μg] / [ml],3.8,75824,DB00603,Medroxyprogesterone Acetate
,10701698,solubilities,"Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),[μg] / [ml],1.1,75825,DB00603,Medroxyprogesterone Acetate
,10701698,hepatic intrinsic clearances,"Assuming the well-stirred model, hepatic intrinsic clearances of FMPA and MPA were estimated to be 64 and 293 L/h per kg, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),[l] / [h·kg],64,75826,DB00603,Medroxyprogesterone Acetate
,10701698,hepatic intrinsic clearances,"Assuming the well-stirred model, hepatic intrinsic clearances of FMPA and MPA were estimated to be 64 and 293 L/h per kg, respectively.",Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701698/),[l] / [h·kg],293,75827,DB00603,Medroxyprogesterone Acetate
>,25257727,trough concentrations,"Despite dose escalation in 90 % of patients, only 17 (57 %) patients ever achieved MPA trough concentrations >50 ng/ml.",A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25257727/),[ng] / [ml],50,89376,DB00603,Medroxyprogesterone Acetate
,2971841,half-lives,"MPA was distributed very rapidly into three compartments after i.v. injections, revealing half-lives of 4-7 h.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),h,4-7,94522,DB00603,Medroxyprogesterone Acetate
,2971841,metabolic clearance rates (MCR),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),[1] / [d],652,94523,DB00603,Medroxyprogesterone Acetate
,2971841,metabolic clearance rates (MCR),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),[1] / [d],601,94524,DB00603,Medroxyprogesterone Acetate
,2971841,distribution volumes (V0),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),,5.9,94525,DB00603,Medroxyprogesterone Acetate
,2971841,distribution volumes (V0),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),,3.41,94526,DB00603,Medroxyprogesterone Acetate
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],3.4,100284,DB00603,Medroxyprogesterone Acetate
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],10.5,100285,DB00603,Medroxyprogesterone Acetate
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],420.6,100286,DB00603,Medroxyprogesterone Acetate
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],775.0,100287,DB00603,Medroxyprogesterone Acetate
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.0042,100288,DB00603,Medroxyprogesterone Acetate
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.074,100289,DB00603,Medroxyprogesterone Acetate
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],1.9,100290,DB00603,Medroxyprogesterone Acetate
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.05,100291,DB00603,Medroxyprogesterone Acetate
,18061638,ED50,The estimated plasma concentration of dienogest at ED50 (3.66 nmol/l) was close to its EC50 value to activate PR.,Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],3.66,100292,DB00603,Medroxyprogesterone Acetate
,8725700,Serum concentrations,"Serum concentrations vary between individual women but generally plateau at about 1.0 ng/mL for about three months, after which there is a gradual decline.",Pharmacokinetics of depot medroxyprogesterone acetate contraception. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8725700/),[ng] / [ml],1.0,111745,DB00603,Medroxyprogesterone Acetate
,1535103,Css min,"A wide interpatient variability was noted in MPA Css min for the 70 patients who received 1,000 mg/d orally (median, 51 ng/mL; range, 10 to 269 ng/mL).",Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535103/),[ng] / [ml],51,124372,DB00603,Medroxyprogesterone Acetate
,1535103,Css min,These data suggested an optimal therapeutic window for MPA Css min located within 50 to 70 ng/mL.,Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535103/),[ng] / [ml],50 to 70,124373,DB00603,Medroxyprogesterone Acetate
,10640166,trough concentrations (Cmin),"More important, the average MPA trough concentrations (Cmin) at the fifth and sixth monthly injections were similar (range 0.42-0.51 ng/mL) for the three injection sites and well above the threshold levels of 0.10-0.20 ng/mL required to suppress ovulation.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640166/),[ng] / [ml],0.42-0.51,125425,DB00603,Medroxyprogesterone Acetate
,10640166,trough concentrations (Cmin),"More important, the average MPA trough concentrations (Cmin) at the fifth and sixth monthly injections were similar (range 0.42-0.51 ng/mL) for the three injection sites and well above the threshold levels of 0.10-0.20 ng/mL required to suppress ovulation.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640166/),[ng] / [ml],0.10-0.20,125426,DB00603,Medroxyprogesterone Acetate
,4028723,maximum level,The (geometric) mean maximum level of MPA was 2.9 (2.4-3.7) nmol/1 and that of NET 10.1 (6.4-15.8) nmol/l.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),nM,2.9,148043,DB00603,Medroxyprogesterone Acetate
,4028723,maximum level,The (geometric) mean maximum level of MPA was 2.9 (2.4-3.7) nmol/1 and that of NET 10.1 (6.4-15.8) nmol/l.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[nM] / [l],10.1,148044,DB00603,Medroxyprogesterone Acetate
,4028723,maximum level,The maximum level of exogenous E2 was 890 (700-1130) pmol/l after Cycloprovera and 1570 (870-2820) pmol/l after HRP-102 administration.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[pM] / [l],890,148045,DB00603,Medroxyprogesterone Acetate
,4028723,maximum level,The maximum level of exogenous E2 was 890 (700-1130) pmol/l after Cycloprovera and 1570 (870-2820) pmol/l after HRP-102 administration.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[pM] / [l],1570,148046,DB00603,Medroxyprogesterone Acetate
,23993431,AUC0-91,Mean AUC0-91 was 45.1 ng·day/mL.,Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23993431/),[d·ng] / [ml],45.1,154382,DB00603,Medroxyprogesterone Acetate
,10640167,Cmax,The mean MPA Cmax and AUC0-t(last) were 1.25 ng/mL and 32.13 ng.,Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),[ng] / [ml],1.25,161972,DB00603,Medroxyprogesterone Acetate
,10640167,AUC0-t(last),The mean MPA Cmax and AUC0-t(last) were 1.25 ng/mL and 32.13 ng.,Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),ng,32.13,161973,DB00603,Medroxyprogesterone Acetate
,10640167,terminal half-life,"Serum MPA concentrations declined with a mean terminal half-life of 14.7 days, indicating that absorption from the injection site is prolonged after administration of MPA/E2C.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),d,14.7,161974,DB00603,Medroxyprogesterone Acetate
,10640167,trough (Cmin' day 28) concentrations,"The average MPA trough (Cmin' day 28) concentrations for the three consecutive monthly injections ranged from 0.44 to 0.47 pg/mL, indicating that steady-state conditions were achieved after the first injection.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),[pg] / [ml],0.44 to 0.47,161975,DB00603,Medroxyprogesterone Acetate
,10640167,Cmax,"Mean concentrations of E2 peaked at approximately 2 days after the third injection, and the average Cmax was 247 pg/mL.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),[pg] / [ml],247,161976,DB00603,Medroxyprogesterone Acetate
,10640167,terminal half-life,"Serum E2 levels declined with a terminal half-life of approximately 8 days; E2 levels returned to baseline (typically, approximately 100 pg/mL) by 14 days after each injection.",Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),d,8,161977,DB00603,Medroxyprogesterone Acetate
,10640167,trough (Cmin' day 28),The average trough (Cmin' day 28) levels for E2 ranged from 40 to 55 pg/mL.,Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640167/),[pg] / [ml],40 to 55,161978,DB00603,Medroxyprogesterone Acetate
,15385829,Cmax,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,104.89,184428,DB00603,Medroxyprogesterone Acetate
,15385829,Cmax,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,103.27,184429,DB00603,Medroxyprogesterone Acetate
,15385829,AUC0-24,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,1900.30,184430,DB00603,Medroxyprogesterone Acetate
,15385829,AUC0-24,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,1783.70,184431,DB00603,Medroxyprogesterone Acetate
,15385829,AUC0-infinity,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,5576.06,184432,DB00603,Medroxyprogesterone Acetate
,15385829,AUC0-infinity,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,5317.89,184433,DB00603,Medroxyprogesterone Acetate
,15385829,ka,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,1.06,184434,DB00603,Medroxyprogesterone Acetate
,15385829,ka,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,1.09,184435,DB00603,Medroxyprogesterone Acetate
,15385829,t1/2,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,35.65,184436,DB00603,Medroxyprogesterone Acetate
,15385829,t1/2,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,36.12,184437,DB00603,Medroxyprogesterone Acetate
,15385829,MRT,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,16.29,184438,DB00603,Medroxyprogesterone Acetate
,15385829,MRT,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,16.27,184439,DB00603,Medroxyprogesterone Acetate
,15385829,V/F,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,16.29,184440,DB00603,Medroxyprogesterone Acetate
,15385829,V/F,"From these data, the following pharmacokinetic parameters were calculated for E2 alone and E2 in combination with MPA (E2V/MPA): Cmax = 104.89 +/- 26.96, 103.27 +/- 44.40; AUC0-24 =1900.30 +/- 392.23, 1783.70 +/- 756.39; AUC0-infinity = 5576.06 +/- 4065.87, 5317.89 +/- 3702.54; ka = 1.06 +/- 0.31, 1.09 +/- 0.13; t1/2 = 35.65 +/- 20.62, 36.12 +/- 18.04; MRT = 16.29 +/- 8.77, 16.27 +/- 4.88; V/F = 16.29 +/- 8.76, 16.27 +/- 4.88.",A comparative pharmacokinetic study of micronized estradiol valerate administered alone and in combination with medroxyprogesterone acetate in postmenopausal women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385829/),,16.27,184441,DB00603,Medroxyprogesterone Acetate
,2943134,half-life of the absorption process,Following oral administration MPA is rapidly transferred from the gastrointestinal tract to the blood circulation with a half-life of the absorption process of 15-30 min.,Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),min,15-30,199005,DB00603,Medroxyprogesterone Acetate
,2943134,biological half-life,"The peak plasma concentration is reached 1-3 hrs after administration, and the biological half-life of MPA is 40-60 hrs.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),h,40-60,199006,DB00603,Medroxyprogesterone Acetate
,2943134,areas under the plasma concentration-time curves (AUC 0-infinity),"Following administration of 1000 mg MPA the areas under the plasma concentration-time curves (AUC 0-infinity) were calculated to (mean and S.E.): 3357 (438) nmol/l and 2403 (245) nmol/l for Leo formulation A and Farlutal, respectively (P less than 0.02).",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],3357,199007,DB00603,Medroxyprogesterone Acetate
,2943134,areas under the plasma concentration-time curves (AUC 0-infinity),"Following administration of 1000 mg MPA the areas under the plasma concentration-time curves (AUC 0-infinity) were calculated to (mean and S.E.): 3357 (438) nmol/l and 2403 (245) nmol/l for Leo formulation A and Farlutal, respectively (P less than 0.02).",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],2403,199008,DB00603,Medroxyprogesterone Acetate
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],2325,199009,DB00603,Medroxyprogesterone Acetate
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],1793,199010,DB00603,Medroxyprogesterone Acetate
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],1778,199011,DB00603,Medroxyprogesterone Acetate
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],1178,199012,DB00603,Medroxyprogesterone Acetate
,2943134,areas,"Following administration of 500 mg the areas were: 2325 (389) nmol/l, 1793 (312) nmol/l, 1778 (239) nmol/l, 1178 (209) nmol/l, and 556 (89) nmol/l for Gestapuran, Leo formulation A (P = n.s.), Leo formulation B (P = n.s.), Provera (P less than 0.001), and Lutopolar (P less than 0.001), respectively.",Medroxyprogesterone acetate pharmacokinetics following oral high-dose administration in humans: a bioavailability evaluation of a new MPA tablet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943134/),[nM] / [l],556,199013,DB00603,Medroxyprogesterone Acetate
,939191,MPA,The MCRMPA (696 +/- 51 l/day) was only one-half that of progesterone (1332 +/- 59).,The in vivo metabolism of progestins. I. The metabolic clearance rates of progesterone and medroxyprogesterone acetate in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/939191/),[l] / [d],696,208628,DB00603,Medroxyprogesterone Acetate
,939191,MPA,The MCRMPA (696 +/- 51 l/day) was only one-half that of progesterone (1332 +/- 59).,The in vivo metabolism of progestins. I. The metabolic clearance rates of progesterone and medroxyprogesterone acetate in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/939191/),,1332,208629,DB00603,Medroxyprogesterone Acetate
,2522811,survival time,The median survival time was significantly longer for responders (19.9 months) than nonresponders (4.8 months).,High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522811/),month,19.9,216216,DB00603,Medroxyprogesterone Acetate
,2522811,survival time,The median survival time was significantly longer for responders (19.9 months) than nonresponders (4.8 months).,High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522811/),month,4.8,216217,DB00603,Medroxyprogesterone Acetate
,15208047,time for return to o,"Median time for return to ovulation was 30 weeks, with a 97.4% cumulative rate of return to ovulation at 12 months.","Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15208047/),weeks,30,218545,DB00603,Medroxyprogesterone Acetate
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,99.94,226877,DB00603,Medroxyprogesterone Acetate
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,69.99,226878,DB00603,Medroxyprogesterone Acetate
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,92.69,226879,DB00603,Medroxyprogesterone Acetate
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,53.51,226880,DB00603,Medroxyprogesterone Acetate
,22018130,T(max),The in vivo results showed prolonged T(max) of 36 h for both EE and MPA after transdermal administration compared to oral route (2 h).,Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),h,36,226881,DB00603,Medroxyprogesterone Acetate
,22018130,T(max),The in vivo results showed prolonged T(max) of 36 h for both EE and MPA after transdermal administration compared to oral route (2 h).,Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),h,2,226882,DB00603,Medroxyprogesterone Acetate
,8173196,Css min,"A wide inter-patient variability was noted in MPA Css min for the 70 patients receiving 1000 mg/day per os: median 51 ng/ml, range 10-269 ng/ml.",[Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173196/),[ng] / [ml],51,243395,DB00603,Medroxyprogesterone Acetate
,8173196,Css min,These data suggested an optimal therapeutic window for MPA Css min located within 50-70 ng/ml.,[Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8173196/),[ng] / [ml],50-70,243396,DB00603,Medroxyprogesterone Acetate
<,9619751,AUC,Five patients demonstrated extremely low AUC and Cmax (< 10 ng/ml) values on day 1.,Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619751/),[ng] / [ml],10,257240,DB00603,Medroxyprogesterone Acetate
<,9619751,Cmax,Five patients demonstrated extremely low AUC and Cmax (< 10 ng/ml) values on day 1.,Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619751/),[ng] / [ml],10,257241,DB00603,Medroxyprogesterone Acetate
,9693401,maximum serum concentrations (Cmax),"After the 1st, 6th, and 12th injection, the maximum serum concentrations (Cmax) of MPA were observed on days 3.4 +/- 0.9, 4.3 +/- 2.2, and 3.7 +/- 2.6, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),,3.4,257830,DB00603,Medroxyprogesterone Acetate
,9693401,maximum serum concentrations (Cmax),"After the 1st, 6th, and 12th injection, the maximum serum concentrations (Cmax) of MPA were observed on days 3.4 +/- 0.9, 4.3 +/- 2.2, and 3.7 +/- 2.6, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),,4.3,257831,DB00603,Medroxyprogesterone Acetate
,9693401,maximum serum concentrations (Cmax),"After the 1st, 6th, and 12th injection, the maximum serum concentrations (Cmax) of MPA were observed on days 3.4 +/- 0.9, 4.3 +/- 2.2, and 3.7 +/- 2.6, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),,3.7,257832,DB00603,Medroxyprogesterone Acetate
,9693401,Cmax,"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [l],3.75,257833,DB00603,Medroxyprogesterone Acetate
,9693401,Cmax,"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [l],5.54,257834,DB00603,Medroxyprogesterone Acetate
,9693401,Cmax,"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [l],5.55,257835,DB00603,Medroxyprogesterone Acetate
,9693401,areas under the curve (AUC0-28 days),"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [d·l],55.84,257836,DB00603,Medroxyprogesterone Acetate
,9693401,areas under the curve (AUC0-28 days),"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [d·l],95.45,257837,DB00603,Medroxyprogesterone Acetate
,9693401,areas under the curve (AUC0-28 days),"Cmax of serum MPA during the 1st, 6th, and 12th treatment cycles were 3.75 +/- 1.27, 5.54 +/- 1.79, and 5.55 +/- 1.80 nmol/L, whereas the areas under the curve (AUC0-28 days) were 55.84 +/- 28.15, 95.45 +/- 26.56, and 98.81 +/- 21.84 nmol/L.day, respectively.",Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9693401/),[nM] / [d·l],98.81,257838,DB00603,Medroxyprogesterone Acetate
,31504342,clearance,The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls.,Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31504342/),[l] / [week],19 681,261371,DB00603,Medroxyprogesterone Acetate
,31504342,clearance,The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls.,Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31504342/),[l] / [week],12 118,261372,DB00603,Medroxyprogesterone Acetate
,898233,plasma MCR6MP,"The plasma MCR6MP was 4047 +/- 298 L/day (59 +/- 15 L/day/kg) which was higher than the MCR of progesterone and medroxyprogesterone acetate (6alpha-methyl-17alpha-hydroxy-pregna-4-ene-3,20-dione acetate).","The in vivo metabolism of progestins. The metabolic clearance rate and plasma binding of 6alpha-methylpregn-4-ene-3, 20-dione in women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/898233/),[l] / [d],4047,261773,DB00603,Medroxyprogesterone Acetate
,898233,plasma MCR6MP,"The plasma MCR6MP was 4047 +/- 298 L/day (59 +/- 15 L/day/kg) which was higher than the MCR of progesterone and medroxyprogesterone acetate (6alpha-methyl-17alpha-hydroxy-pregna-4-ene-3,20-dione acetate).","The in vivo metabolism of progestins. The metabolic clearance rate and plasma binding of 6alpha-methylpregn-4-ene-3, 20-dione in women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/898233/),[l] / [d·kg],59,261774,DB00603,Medroxyprogesterone Acetate
,8499584,disposition half-lives,"Dog plasma MPA levels from the intravenous dose were characterized by a triexponential decay with disposition half-lives of 0.3, 1.8, and 21.6 h.",Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499584/),h,0.3,271715,DB00603,Medroxyprogesterone Acetate
,8499584,disposition half-lives,"Dog plasma MPA levels from the intravenous dose were characterized by a triexponential decay with disposition half-lives of 0.3, 1.8, and 21.6 h.",Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499584/),h,1.8,271716,DB00603,Medroxyprogesterone Acetate
,8499584,disposition half-lives,"Dog plasma MPA levels from the intravenous dose were characterized by a triexponential decay with disposition half-lives of 0.3, 1.8, and 21.6 h.",Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499584/),h,21.6,271717,DB00603,Medroxyprogesterone Acetate
,8499584,absolute bioavailability,"The oral absorption of MPA in dogs appears to be dose-linear over the dosage range studied, and the absolute bioavailability was estimated at 27 per cent.",Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499584/),%,27,271718,DB00603,Medroxyprogesterone Acetate
